{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"45.7","value":"114"},{"groupId":"OG001","spread":"49.9","value":"127"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Cycle 1: Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"118","value":"272"},{"groupId":"OG001","spread":"103","value":"263"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Cycle 1: Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"163","value":"388"},{"groupId":"OG001","spread":"206","value":"323"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Cycle 1: Day 22"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"174","value":"475"},{"groupId":"OG001","spread":"209","value":"426"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Cycle 1: Day 29"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"296","value":"504"},{"comment":"Standard deviation (SD) could not be calculated for a single participant.","groupId":"OG001","spread":"NA","value":"357"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Cycle 2: Day 43"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"224","value":"531"},{"groupId":"OG001","spread":"261","value":"478"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Cycle 2: Day 57"}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"Plasma samples were collected at specified timepoints to determine the Ctrough of isatuximab.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with B-ALL received isatuximab 20 mg/kg IV infusion QW for 4 weeks during the induction period (i.e., on Days 1, 8, 15, and 22) and Q2W during the consolidation period (i.e., on Days 29, 43, and 57. Participants received recommended isatuximab premedication as per protocol. Starting on Day 8, combination chemotherapies were added. Participants without documented disease progression at EOT visit who had not started treatment with another anticancer therapy received follow-up visits every 2 months until initiation of another anticancer therapy, disease progression, death, or final analysis cut-off date, whichever occurred first. Participants with documented disease progression/initiation of new anticancer treatment were followed for survival every 4 months until death or final analysis cut-off date, whichever occurred first.","id":"OG000","title":"B-cell Acute Lymphoblastic Leukemia (B-ALL)"},{"description":"Participants with T-ALL received isatuximab 20 mg/kg IV infusion QW for 4 weeks during the induction period (i.e., on Days 1, 8, 15, and 22) and Q2W during the consolidation period (i.e., on Days 29, 43, and 57. Participants received recommended isatuximab premedication as per protocol. Starting on Day 8, combination chemotherapies were added. Participants without documented disease progression at EOT visit who had not started treatment with another anticancer therapy received follow-up visits every 2 months until initiation of another anticancer therapy, disease progression, death, or final analysis cut-off date, whichever occurred first. Participants with documented disease progression/initiation of new anticancer treatment were followed for survival every 4 months until death or final analysis cut-off date, whichever occurred first.","id":"OG001","title":"T-cell Acute Lymphoblastic Leukemia (T-ALL)"}],"paramType":"MEAN","populationDescription":"The PK population consisted of all participants from the AT population with at least 1 PK parameter available (isatuximab concentration). Only those participants with data available at specified timepoints were analyzed.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 8, Cycle 1 Day 15, Cycle 1 Day 22, Cycle 1 Day 29, Cycle 2 Day 43, Cycle 2 Day 57","title":"B-ALL and T-ALL: Plasma Concentration Reached by Isatuximab Before Next Dose Administration (Ctrough)","type":"SECONDARY","unitOfMeasure":"microgram/milliliter (mcg/mL)"}